BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe

Programme: Innovative Medicines Initiative 2 Joint Undertaking grant agreement No 101034369
Duration: 01/09/2021 – 31/08/2026 (60 months)


Patient non-adherence to prescribed treatment poses a formidable health challenge. It affects patient health outcomes significantly, contributing to 200,000 premature deaths in the EU annually, and places a heavy economic burden on the healthcare system, leading to an estimated 125B euros in avoidable hospitalisations, emergency care and adult outpatient visits each year. Despite existing research on disease-specific medication adherence, there are few broad insights regarding how to improve adherence across healthcare. To address this, BEAMER aims to acquire a comprehensive understanding of the factors that influence patient adherence, irrespective of the therapeutic area, and enable stakeholders to design effective solutions that could promote broad and consistent impact within a real-world context.

To achieve these objectives, the project will create a generalised model of the significant factors affecting non-adherent behaviour, grounded in behavioural theory. This will allow the project team to define the problem of non-adherence and provide guidance for healthcare stakeholders to develop and implement cost-effective tools and solutions that directly target patient needs, potentially contributing to enhanced patient outcomes and reduced health system costs. Although disease-agnostic,  the model is intended to be tailorable with disease-specific inputs to increase its prediction power and optimise patient support strategies. This degree of flexibility would then enable the model to be widely applicable and responsive to ongoing changes in various populations.

Scope and objectives

The BEAMER’s vision is to improve the quality of life of individuals, enhance healthcare accessibility and sustainability, thereby transforming the way healthcare stakeholders engage with patients to understand their condition and adherence levels throughout their healthcare journey. An outstanding experienced consortium supports the BEAMER vision with the following specific objectives organized in four phases. These objectives are fully aligned to the IMI Call topic.

ECHAlliance role

The ECHAlliance is the Communications Dissemination Manager of BEAMER; leading the task 6.7. Communications & Dissemination.


BEAMER is a public – private partnership with 28 members from Europe, co-led by University of Porto (coordinator) and Pfizer (industry lead), funded by the Innovative Medicines Initiative (IMI) – a joint undertaking of the European Commission, the European Federation of Pharmaceutical Industries and Associations (EFPIA), IMI Associated Partners.


Social Media


Become a member now